Public-registry site landscape for NCT04887870, “Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent Study”, a Advanced or Metastatic Solid Malignancies study sponsored by Mirati Therapeutics Inc.. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT04887870 (registry record) |
| Study title | Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent Study |
| Official title | A Multicenter, Open-label Rollover Study of Sitravatinib Alone or in Combination With Other Anticancer Therapies in Patients With Advanced or Metastatic Solid Malignancies |
| Sponsor | Mirati Therapeutics Inc. |
| Condition(s) | Advanced or Metastatic Solid Malignancies |
| Phase | PHASE2 / PHASE3 |
| Listed sites | 13 |
| Site countries | United States |
Patient-friendly overview of this study: eichor.com/study/NCT04887870.
Eichor generates a preliminary site-risk snapshot for NCT04887870 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
